Aldosterone and vasopressin differ in where they act, how they act, and what they regulate. Vasopressin (antidiuretic hormone) inserts water channels called aquaporin-2 into kidney collecting-duct cells, reclaiming free water and concentrating urine. Aldosterone instead drives sodium reabsorption and potassium secretion through ENaC and the Na+/K+ pump, mostly in the distal nephron, and water follows the sodium. In plain terms: vasopressin manages water balance by conserving water itself, while aldosterone manages salt balance and blood pressure by conserving sodium.
The core mechanism: water channels versus sodium pumps
Vasopressin is a nine-amino-acid peptide made in the hypothalamus and released from the posterior pituitary. It binds V2 receptors on the basolateral membrane of collecting-duct principal cells. That triggers a cyclic AMP cascade that phosphorylates aquaporin-2, trafficking it to the luminal membrane.
The result is measurable. A maximally concentrated human urine reaches roughly 1,200 to 1,400 mOsm/kg, against a plasma osmolality near 290 mOsm/kg. That is a fourfold to fivefold concentrating gradient. Each aquaporin-2 channel can pass on the order of 10⁹ water molecules per second, which is why the response is fast.
Aldosterone works on a slower timescale and a different target. It is a steroid, so it crosses the cell membrane and binds the mineralocorticoid receptor inside principal cells of the late distal tubule and collecting duct. The genomic response raises ENaC channel abundance and Na+/K+ ATPase expression over hours.
Its acute, non-genomic effects appear within 15 to 30 minutes. The classic teaching that aldosterone acts only genomically was revised after 2000. The rapid effects include ENaC activation through the glucocorticoid-induced kinase SGK1.
In plain terms: vasopressin opens a water door in minutes; aldosterone builds more sodium pumps over hours.
One non-obvious detail sits at the receptor. Cortisol circulates at 100 to 1,000 times the concentration of aldosterone. The enzyme 11-beta-hydroxysteroid dehydrogenase type 2 converts cortisol to cortisone inside the kidney, protecting the mineralocorticoid receptor. When this enzyme is inhibited, as with licorice, cortisol floods the receptor and produces apparent mineralocorticoid excess: hypertension and low potassium.
Quantified comparison: the numbers side by side
| Feature | Aldosterone | Vasopressin |
|---|---|---|
| Chemical class | Steroid (mineralocorticoid) | Peptide (9 amino acids) |
| Source | Zona glomerulosa, adrenal cortex | Hypothalamus; released by posterior pituitary |
| Primary trigger | Angiotensin II, hyperkalemia | Plasma osmolality above about 280-290 mOsm/kg; volume loss |
| Main receptor | Mineralocorticoid receptor (intracellular) | V2 receptor (kidney), V1a (vessels) |
| Effector | ENaC, Na+/K+ ATPase | Aquaporin-2 water channels |
| Nephron site | Late distal tubule, collecting duct | Collecting duct principal cells |
| Onset | 15-30 min non-genomic; 1-2 h genomic | 5-15 min |
| Half-life in plasma | About 15-20 min | About 10-20 min |
| Daily secretion | Roughly 100-200 micrograms | Roughly 1-2 micrograms |
| Dominant action | Sodium retention, potassium excretion | Free water reabsorption |
| Clinical excess | Primary aldosteronism: hypertension, low potassium | SIADH: dilutional hyponatremia |
| Clinical deficiency | Addison disease: salt wasting, high potassium | Central diabetes insipidus: high-volume dilute urine |
The secretion gap is the striking quantified comparison. Aldosterone circulates at microgram-per-day rates, while vasopressin operates at nanogram-to-microgram rates, yet vasopressin acts on a faster clock. Potency and speed are decoupled.
When the two systems pull in opposite directions
Volume depletion is the clearest case of coordination. A 10 percent fall in blood volume removes roughly 10 to 15 percent of atrial stretch, dropping atrial natriuretic peptide. Simultaneously, baroreceptor unloading raises sympathetic tone, activates renin, and releases vasopressin.
Aldosterone then reclaims sodium, and vasopressin reclaims water. The urine output can fall below 500 mL per day, and urine osmolality climbs above 500 mOsm/kg. The two hormones cooperate here, and the result is concentrated urine that is both low in sodium and low in volume.
The systems diverge in other states. In primary aldosteronism, aldosterone excess expands volume and suppresses renin. Vasopressin is suppressed by the volume expansion, yet the patient remains hypertensive. The "escape" from sodium retention comes partly from pressure natriuresis, not from a drop in aldosterone.
SIADH is the mirror image. Vasopressin is inappropriately high despite low osmolality, so water is retained and plasma sodium falls. Aldosterone is normal or suppressed because volume is expanded. The fix is fluid restriction, not a diuretic aimed at aldosterone.
In plain terms: aldosterone and vasopressin usually work as a team, but each can misbehave alone.
The timeline: what happens after a trigger
| Time after trigger | Aldosterone response | Vasopressin response |
|---|---|---|
| 0-2 minutes | Receptor binding begins | V2 receptor coupling to Gs protein |
| 5-15 minutes | Non-genomic ENaC activation | Aquaporin-2 insertion; urine osmolality rises |
| 15-30 minutes | SGK1-mediated channel upregulation | Peak water permeability; urine flow falls |
| 1-2 hours | Genomic transcription of ENaC and Na+/K+ ATPase | Sustained concentration; vasopressin release adjusts to osmolality |
| 2-6 hours | Sodium reabsorption increases; potassium secretion rises | Maximal urine concentration near 1,200 mOsm/kg |
| 12-24 hours | Full protein abundance change | Feedback via osmoreceptors stabilizes plasma sodium |
| Days | Blood pressure and potassium set point shift | Chronic adaptation; escape mechanisms limit water retention |
The timeline is the practical clue for clinicians. A patient with a urine osmolality that jumps within 30 minutes of a stimulus is showing a vasopressin effect. A rise in sodium reabsorption over hours, with a fall in potassium, points toward aldosterone.
Misconceptions and edge cases
A common error is treating the two hormones as interchangeable "water retainers." They are not. Vasopressin without aldosterone can cause hyponatremia with normal volume, as in SIADH. Aldosterone without vasopressin can cause hypertension with normal or high sodium, as in primary aldosteronism.
Another misconception is that aldosterone acts only in the kidney. Mineralocorticoid receptors are also found in the heart, vasculature, and colon. This is why mineralocorticoid receptor antagonists such as spironolactone lower blood pressure beyond what diuresis alone explains.
The potassium side is underappreciated. Aldosterone excess drives potassium secretion. A serum potassium below 3.0 mmol/L in a hypertensive patient should prompt a workup for primary aldosteronism, not just a potassium supplement. The 2016 Endocrine Society guideline recommends screening for primary aldosteronism in resistant hypertension.
Vasopressin has its own trap. The osmoreceptor set point shifts by about 1 percent per unit change in osmolality, and older adults have a blunted thirst response. A 2022 review in the journal Age and Ageing noted that this makes dehydration and hyponatremia more likely in the elderly, even with normal vasopressin regulation.
Red-flag signs that these systems are failing:
- Confusion or seizures with sodium below 120 mmol/L or above 155 mmol/L.
- Blood pressure above 180/120 mmHg with a low potassium.
- Urine output above 3 liters per day with dilute urine, suggesting diabetes insipidus.
- Sudden weight gain of more than 2 kilograms in a week with swelling and low sodium.
- Potassium above 5.5 mmol/L with low blood pressure, suggesting adrenal insufficiency.
- No urine for 12 hours with rising creatinine, suggesting a pre-renal or obstructive crisis.
What to actually do
If you are a patient, the practical steps depend on which axis appears disturbed. For suspected aldosterone excess, ask for a plasma aldosterone concentration with plasma renin activity; the aldosterone-to-renin ratio is the standard screen. The 2016 Endocrine Society guideline favors this test before starting a mineralocorticoid receptor antagonist, since those drugs interfere with the result.
For suspected vasopressin excess or deficiency, the workup is a paired serum and urine osmolality. In SIADH, urine osmolality is typically above 100 mOsm/kg while serum osmolality is below 275 mOsm/kg. In central diabetes insipidus, urine osmolality stays below 200 mOsm/kg after water deprivation.
Do not self-treat with salt tablets or water loading. Both can worsen the opposite axis. A patient with SIADH who adds salt without addressing vasopressin may still dilute, and a patient with aldosterone excess who restricts sodium may not fix the potassium.
Positive actions that apply to most people: keep sodium intake between 1,500 and 2,300 mg per day unless a clinician sets a different target, and monitor blood pressure at home. For those on mineralocorticoid receptor antagonists, check potassium and creatinine within one week of starting and after any dose change.
Limitations and open questions
Not every number here is settled. The exact contribution of non-genomic aldosterone signaling to human blood pressure is still debated. Animal models suggest rapid effects matter, but human trials have not cleanly separated them from genomic effects.
The vasopressin side has its own uncertainty. The osmostat set point varies between individuals by up to 5 mOsm/kg, which is why a plasma sodium of 137 mmol/L can be normal for one person and abnormal for another. Reference ranges are population averages, not individual truths.
The interplay between the two systems also remains incompletely mapped. Some evidence suggests aldosterone can influence aquaporin-2 expression indirectly, but the magnitude in humans is unknown. Until better data arrive, the safest clinical stance is to treat them as related but distinct axes, each with its own diagnostic tests and its own red flags.